From e5e052db3501936422c760ec8f88d993a7e20ccb Mon Sep 17 00:00:00 2001
From: Will King <will@youainti.com>
Date: Fri, 30 Aug 2024 09:34:18 -0700
Subject: [PATCH] updated introduction

---
 Latex/Paper/Main.tex                     |  3 ++
 Latex/Paper/sections/01_introduction.tex | 39 +++++++++++++++++++-----
 2 files changed, 35 insertions(+), 7 deletions(-)

diff --git a/Latex/Paper/Main.tex b/Latex/Paper/Main.tex
index e2da6b2..8a667ca 100644
--- a/Latex/Paper/Main.tex
+++ b/Latex/Paper/Main.tex
@@ -26,6 +26,9 @@
 \title{The effects of market conditions on enrollment and completion of clinical trials\\ \small{Preliminary Draft}}
 \author{William King}
 
+\usepackage{multirow}
+\usepackage{multicol}
+
 \begin{document}
 \maketitle
 
diff --git a/Latex/Paper/sections/01_introduction.tex b/Latex/Paper/sections/01_introduction.tex
index 40f2b2a..b01c214 100644
--- a/Latex/Paper/sections/01_introduction.tex
+++ b/Latex/Paper/sections/01_introduction.tex
@@ -12,15 +12,35 @@ and fiscal policy question that has been debated for
 decades.
 Due to the complicated legal and competitive landscape, unintended consequences
 are common 
-\cite{van_der_gronde_addressing_2017}.
-One critical aspect to successfully introduce a novel pharmaceutical or even
-a generic compound is to establish that the drug as packaged and sold will
+\cite{vandergronde_addressingchallengehighpriced_2017}.
+One essential step to introduce a novel pharmaceutical - or even
+to begin selling a generic compound - is to establish that the drug as packaged and sold will
 have acceptable safety and efficacy profiles.
-This is done using clinical trials.
+When evaluating these compounds in a clinical trial, both outcomes are possible:
+\begin{enumerate}
+    \item The compound demonstrates sufficient safety and efficacy, and proceeds in the appoval process. \ref{Item:EndSuccess}
+    \item The compound fails to demonstrate sufficient safety and efficacy, and the approval process halts. \ref{Item:EndFail}
+    \item The trial is terminated before it can acheive one of the first two outcomes, for reasons unrelated to safety and efficacy concerns. \label{Item:Terminate}
+\end{enumerate}
+
+\begin{table}
+    \caption{}\label{tab:}
+    \begin{center}
+        \begin{tabular}{p{0.4\textwidth}|p{0.3\textwidth}|p{0.3\textwidth}|}
+        \cline{2-3}
+          \multirow{2}{*}{}  & \multicolumn{2}{c|}{Drug-Indication Match} \\
+        \cline{2-3}
+            & safe and efficacious & not safe nor efficatious \\
+        \hline
+        \multirow{2}{*}{Discovery process} & Known good & Known bad \\
+        \cline{2-3}
+            & Unknown & Unkown \\
+        \cline{2-3}
+        \end{tabular}
+    \end{center}
+\end{table}
+
 
-To adequately guide public policy it is crucial that robust, causally-identified
-statistical models are available to describe the interaction between
-various players within the space.
 While it is known that pharmaceutical companies withdraw some drugs from
 their development pipeline due to commercialization concerns 
 (
@@ -34,6 +54,11 @@ the market, patients might be loath to enroll in clinical trials,
 causing the trial to fail for reasons unrelated to the scientific or
 commercial viability of the therapy.
 
+
+To adequately guide public policy it is crucial that robust, causally-identified
+statistical models are available to describe the interaction between
+various players within the space.
+
 This work endeavors to estimate the change in probability of successful completion
 of a clinical trial due to the existence of alternative drugs on the market. 
 In particular, it seeks to establish whether such an impact is mediated